Ironwood Pharmaceuticals reported a challenging fourth quarter and full year 2025, with significant declines in total revenue and collaboration revenue driven by pricing headwinds and rebate reserve adjustments. Despite these revenue pressures, the company managed to improve GAAP net income year-over-year and generated strong cash flow from operations, ending the year with a solid cash position. Management reiterated a positive outlook for 2026, expecting increased LINZESS U.S. net sales and substantial adjusted EBITDA growth.
GAAP net income improved to $24.0 million for the full year 2025, up from $0.9 million in 2024.
positiveGenerated $127.0 million in cash from operations for the full year 2025, an increase from $103.5 million in 2024.
positiveEnded the year with $215.5 million in cash and cash equivalents, a significant increase from $88.6 million at the end of 2024.
positiveLINZESS prescription demand grew 11% for the full year 2025 and 13% in Q4 2025.
positiveFDA approved LINZESS for IBS-C in patients aged 7 years and older, expanding its clinical utility.
positiveTotal revenue decreased by 15.7% to $296.2 million for the full year 2025, down from $351.4 million in 2024.
negativeCollaboration revenue to Ironwood decreased by 15% to $289.3 million for the full year 2025, down from $340.4 million in 2024.
negativeLINZESS U.S. net sales decreased by 6% to $864.5 million for the full year 2025, down from $916.3 million in 2024.
negativeLINZESS commercial margin decreased to 54% in Q4 2025 from 64% in Q4 2024, driven by unfavorable gross-to-net rebate reserves and net pricing headwinds.
attentionNet profit for the LINZESS U.S. brand collaboration decreased by 4% to $545.4 million for the full year 2025, down from $570.9 million in 2024.
negativeRecorded a $12.5 million charge as SG&A expense in connection with the Ferring settlement for the full year 2025.
negativeMargin expansion indicates improving profitability and operational efficiency. Measured in basis points (bps): 100 bps = 1.0%.
Forward-looking guidance is subject to change and does not constitute a guarantee. Actual results may differ materially from these estimates.
Special items are non-recurring events that may distort period-over-period comparisons. Analysts typically adjust for these when calculating normalized earnings.
LINZESS delivered 11% EUTRx demand growth year-over-year, continuing to strengthen its position as the prescription market leader.
Disciplined approach to expense management allowed us to navigate LINZESS pricing headwinds, deliver $24 million in GAAP net income and $138 million in adjusted EBITDA and generate $127 million in cash flow from operations.
We ended 2025 with $215 million in cash and cash equivalents, positioning Ironwood well for 2026.
Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.
Operational metrics provide insight into business drivers and customer engagement beyond traditional financial measures.